+

WO2004063344A3 - CATALYTIC DOMAINS OF β/1,4)-GALACTOSYLTRANSFERASE I HAVING ALTERED DONOR AND ACCEPTOR SPECIFICITIES, DOMAINS THAT PROMOTE IN VITRO PROTEIN FOLDING, AND METHODS FOR THEIR USE - Google Patents

CATALYTIC DOMAINS OF β/1,4)-GALACTOSYLTRANSFERASE I HAVING ALTERED DONOR AND ACCEPTOR SPECIFICITIES, DOMAINS THAT PROMOTE IN VITRO PROTEIN FOLDING, AND METHODS FOR THEIR USE Download PDF

Info

Publication number
WO2004063344A3
WO2004063344A3 PCT/US2004/000470 US2004000470W WO2004063344A3 WO 2004063344 A3 WO2004063344 A3 WO 2004063344A3 US 2004000470 W US2004000470 W US 2004000470W WO 2004063344 A3 WO2004063344 A3 WO 2004063344A3
Authority
WO
WIPO (PCT)
Prior art keywords
domains
methods
galactosyltransferase
promote
protein folding
Prior art date
Application number
PCT/US2004/000470
Other languages
French (fr)
Other versions
WO2004063344A2 (en
Inventor
Pradman Qasba
Boopathy Ramakrishnan
Original Assignee
Government Of The Us Sercretar
Pradman Qasba
Boopathy Ramakrishnan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The Us Sercretar, Pradman Qasba, Boopathy Ramakrishnan filed Critical Government Of The Us Sercretar
Priority to CA002510550A priority Critical patent/CA2510550A1/en
Priority to EP04701172A priority patent/EP1587919A4/en
Priority to JP2006500866A priority patent/JP2006518192A/en
Priority to AU2004204463A priority patent/AU2004204463B2/en
Publication of WO2004063344A2 publication Critical patent/WO2004063344A2/en
Publication of WO2004063344A3 publication Critical patent/WO2004063344A3/en
Priority to US11/178,230 priority patent/US7482133B2/en
Priority to US12/321,006 priority patent/US20090233345A1/en
Priority to AU2009201883A priority patent/AU2009201883A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01133—Xylosylprotein 4-beta-galactosyltransferase (2.4.1.133)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed are methods and compositions that can be used to synthesize oligosaccharides; mutants of galactosyltransferases having altered donor and acceptor specificity; methods for increasing the immunogenicity of an antigen; and polypeptide stem regions that can be used to promote in vitro folding of polypeptides, such as the catalytic domain from a galactosyltransferase.
PCT/US2004/000470 2003-01-10 2004-01-09 CATALYTIC DOMAINS OF β/1,4)-GALACTOSYLTRANSFERASE I HAVING ALTERED DONOR AND ACCEPTOR SPECIFICITIES, DOMAINS THAT PROMOTE IN VITRO PROTEIN FOLDING, AND METHODS FOR THEIR USE WO2004063344A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002510550A CA2510550A1 (en) 2003-01-10 2004-01-09 Catalytic domains of .beta./1,4)-galactosyltransferase i having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use
EP04701172A EP1587919A4 (en) 2003-01-10 2004-01-09 CATALYTIC DOMAINS OF BETA / 1,4) -GALACTOSYLTRANSFERASE I HAVING MODIFIED DONOR AND ACCEPTOR SPECIFICITIES, DOMAINS THAT FACILITATE FOLDING OF IN VITRO PROTEINS AND METHODS OF USE THEREOF
JP2006500866A JP2006518192A (en) 2003-01-10 2004-01-09 Catalytic domains of beta(1,4)-galactosyltransferase I with altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods of use thereof
AU2004204463A AU2004204463B2 (en) 2003-01-10 2004-01-09 Catalytic domains of beta(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use
US11/178,230 US7482133B2 (en) 2003-01-10 2005-07-08 Catalytic domains of β(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use
US12/321,006 US20090233345A1 (en) 2003-01-10 2009-01-13 Catalytic domains of beta(1,4)-galactosyl transferase i having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use
AU2009201883A AU2009201883A1 (en) 2003-01-10 2009-05-12 Catalytic domains of beta(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43929803P 2003-01-10 2003-01-10
US60/439,298 2003-01-10
US45025003P 2003-02-25 2003-02-25
US60/450,250 2003-02-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/178,230 Continuation US7482133B2 (en) 2003-01-10 2005-07-08 Catalytic domains of β(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use

Publications (2)

Publication Number Publication Date
WO2004063344A2 WO2004063344A2 (en) 2004-07-29
WO2004063344A3 true WO2004063344A3 (en) 2005-05-19

Family

ID=32718075

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/000470 WO2004063344A2 (en) 2003-01-10 2004-01-09 CATALYTIC DOMAINS OF β/1,4)-GALACTOSYLTRANSFERASE I HAVING ALTERED DONOR AND ACCEPTOR SPECIFICITIES, DOMAINS THAT PROMOTE IN VITRO PROTEIN FOLDING, AND METHODS FOR THEIR USE

Country Status (6)

Country Link
US (2) US7482133B2 (en)
EP (1) EP1587919A4 (en)
JP (1) JP2006518192A (en)
AU (2) AU2004204463B2 (en)
CA (1) CA2510550A1 (en)
WO (1) WO2004063344A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785212B2 (en) 2006-02-10 2014-07-22 Life Technologies Corporation Oligosaccharide modification and labeling of proteins

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518192A (en) * 2003-01-10 2006-08-10 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ， ナショナル インステ Catalytic domains of beta(1,4)-galactosyltransferase I with altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods of use thereof
WO2005051429A2 (en) * 2003-11-19 2005-06-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeted conjugates with a modified saccharide linker
WO2005056783A1 (en) * 2003-12-05 2005-06-23 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Catalytic domains of beta(1,4)-galactosyltransferase i having altered metal ion specificity
JP2009531289A (en) * 2006-02-10 2009-09-03 ライフ テクノロジーズ コーポレーション Method for modifying and labeling proteins with oligosaccharides
EP3912642B1 (en) * 2012-10-23 2023-04-12 Synaffix B.V. Modified antibody, antibody-conjugate and process for the preparation thereof
PL2991683T3 (en) 2013-05-02 2020-03-31 Glykos Finland Oy Conjugates of a glycoprotein or a glycan with a toxic payload
US9738726B2 (en) 2013-06-11 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HER2-specific monoclonal antibodies and conjugates thereof
WO2015057065A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
EP2935608A1 (en) 2013-10-14 2015-10-28 SynAffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
EP3058083B1 (en) 2013-10-14 2018-04-11 SynAffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
EP2935611B1 (en) 2013-10-14 2021-07-07 SynAffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
CN103849606B (en) * 2014-01-21 2016-02-10 南京农业大学 A kind of application of galactosyltransferase of orthomutation
EP3097079B1 (en) 2014-01-24 2021-05-12 SynAffix B.V. Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne
WO2015112013A1 (en) 2014-01-24 2015-07-30 Synaffix B.V. Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby
US11078286B2 (en) 2015-09-20 2021-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
AU2017212484C1 (en) * 2016-01-27 2020-11-05 Medimmune, Llc Methods for preparing antibodies with a defined glycosylation pattern
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
US11066479B2 (en) 2016-08-02 2021-07-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
AU2017382883B2 (en) 2016-12-21 2024-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
CA3062238A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
CA3059472A1 (en) 2017-05-19 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
CA3066953A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human mesothelin antibodies and uses in cancer therapy
WO2019126041A1 (en) 2017-12-18 2019-06-27 The General Hospital Corporation Glycoengineering
AU2019291176A1 (en) 2018-06-19 2020-12-10 Glykos Finland Oy Conjugate
CN112672765A (en) 2018-06-29 2021-04-16 格莱科斯生物医药公司 Conjugates
JP7459043B2 (en) 2018-07-12 2024-04-01 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Affinity matured CD22-specific monoclonal antibodies and uses thereof
EP3833684A1 (en) 2018-08-08 2021-06-16 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
SG11202104207TA (en) * 2018-11-08 2021-05-28 Kaleido Biosciences Inc Oligosaccharide compositions and methods of use thereof
CN113490510B (en) 2019-01-08 2025-02-14 美国政府(由卫生和人类服务部的部长所代表) Cross-species single-domain antibodies targeting mesothelin for the treatment of solid tumors
CA3125033A1 (en) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
WO2021081052A1 (en) 2019-10-22 2021-04-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate
WO2021142199A1 (en) 2020-01-09 2021-07-15 Mersana Therapeutics, Inc. Site specific antibody-drug conjugates with peptide-containing linkers
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
WO2022147532A1 (en) 2021-01-04 2022-07-07 Mersana Therapeutics, Inc. B7h4-targeted antibody-drug conjugates and methods of use thereof
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
WO2022261017A1 (en) 2021-06-09 2022-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
WO2023076881A1 (en) 2021-10-26 2023-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
GB202116442D0 (en) 2021-11-15 2021-12-29 Actome Gmbh High-efficacy labeling of antibodies with oligonucleotide labels
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
WO2024238346A1 (en) 2023-05-12 2024-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
WO2025019228A1 (en) 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1937035A (en) * 1930-10-20 1933-11-28 Westinghouse Elec Elevator Co Elevator safety device
US2897920A (en) * 1958-01-28 1959-08-04 Dresser Ind Emergency brake for elevator cars
US3282383A (en) * 1964-06-30 1966-11-01 Triax Co Free-fall safety brake
GB2252545A (en) * 1991-02-06 1992-08-12 Poon Otto L Bi-directional safety brake for elevator
US6446769B1 (en) * 2000-10-02 2002-09-10 Gregory A. Kangiser Braking apparatus for a linear motor driven load
JP2006518192A (en) * 2003-01-10 2006-08-10 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ， ナショナル インステ Catalytic domains of beta(1,4)-galactosyltransferase I with altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods of use thereof
WO2005056783A1 (en) * 2003-12-05 2005-06-23 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Catalytic domains of beta(1,4)-galactosyltransferase i having altered metal ion specificity
EP1721858B1 (en) * 2005-05-09 2008-07-16 Dynatech, Dynamics & Technology, S. L. Catch system for a gradual bidirectional safety device
BRPI0601926B1 (en) * 2005-06-17 2018-06-12 Inventio Aktiengesellschaft BRAKE PARACHUTE DEVICE
ES2473323T3 (en) * 2005-11-08 2014-07-04 Dynatech, Dynamics & Technology, S. L. Coining system for bidirectional progressive safety device

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JENIS DM ET AL.: "Increased activity of a beta-galactosyltransferase in tissues of rats bearing prostate and mammary adenocarcinomas", CANCER BIOCHEM. BIOPHYS., vol. 6, no. 1, 1982, pages 37 - 45, XP008045536 *
KEUSCH J. ET AL.: "The effect IgG glycosylation of altering beta1,4-galactosyltransferase-1 activity in B cells", GLYCOBIOLOGY, vol. 8, no. 12, 1998, pages 1215 - 1220, XP002985597 *
ZHANG SW ET AL.: "Effect of p58GTA on beta-1,4-galactosyltransferase 1 activity and cell cycle in human hepatocarcinoma cells", MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 221, no. 1-2, May 2001 (2001-05-01), pages 161 - 168, XP002985598 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785212B2 (en) 2006-02-10 2014-07-22 Life Technologies Corporation Oligosaccharide modification and labeling of proteins

Also Published As

Publication number Publication date
US20060084162A1 (en) 2006-04-20
EP1587919A2 (en) 2005-10-26
AU2004204463A1 (en) 2004-07-29
WO2004063344A2 (en) 2004-07-29
JP2006518192A (en) 2006-08-10
CA2510550A1 (en) 2004-07-29
US7482133B2 (en) 2009-01-27
AU2009201883A1 (en) 2009-06-04
AU2004204463B2 (en) 2009-02-12
EP1587919A4 (en) 2006-10-11
US20090233345A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
WO2004063344A3 (en) CATALYTIC DOMAINS OF β/1,4)-GALACTOSYLTRANSFERASE I HAVING ALTERED DONOR AND ACCEPTOR SPECIFICITIES, DOMAINS THAT PROMOTE IN VITRO PROTEIN FOLDING, AND METHODS FOR THEIR USE
WO2002042471A3 (en) Methods and materials for the synthesis of organic products
WO2007060548A3 (en) Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870
WO2002072605A3 (en) Expression technology for proteins containing a hybrid isotype antibody moiety
AU2002367589A1 (en) Distillate fuel blends from fischer tropsch products with improved seal swell properties
AU2002301453A1 (en) Distillate fuel blends from Fischer Tropsch products with improved seal swell properties
WO2002043658A3 (en) Fcrn-based therapeutics for the treatment of auto-immune disorders
WO2005012479A3 (en) Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2001043701A3 (en) Cosmetic or dermopharmaceutical compositions containing the n-palmytoyl-gly-hys-lys tripeptide
ATE505542T1 (en) TUMOR-ASSOCIATED ANTIGEN DERIVATIVES OF THE MAGE FAMILY FOR THE PRODUCTION OF FUSION PROTEINS WITH T-HELPER EPITOPES AND COMPOSITIONS FOR VACCINATION
ATE293696T1 (en) MUTATED ALPHA-AMYLASE ENZYMES WITH INCREASED STABILITY
AU9737398A (en) Alpha-amylase mutants
WO2003053465A3 (en) Lyophilized preparation containing antibodies to the egf receptor
AU2002319780A1 (en) Alternative compositions and methods for the culture of stem cells
AU2002235994A1 (en) Method for producing proteins by fermentation of microorganisms from the thermus family, the protein mixture thus obtained and cosmetic compositions containing same
WO2001049728A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
MX9603890A (en) Transgenic production of oligosaccharides and glycoconjugates.
WO2008028601A3 (en) Method for improving the specific effector function of single-chain antigen-recognizing genetic constructs (scarc) through murinization thereof
WO2004093808A3 (en) Novel tumor-associated antigens
WO2002072851A3 (en) Lentiviral packaging constructs
WO2004032877A3 (en) Compositions, organisms and methodologies employing a novel human kinase
IL177179A (en) Fusion protein comprising truncated n-acetylgalactosaminyltransferase 2 (galnact2) and maltose binding domain
WO2001004282A3 (en) Replication-competent anti-cancer vectors
WO2008039838A3 (en) Synthetic streptococcus pneumoniae vaccine
MXPA02007752A (en) Transgenic cells expressing glucosyltransferase nucleic acids.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2510550

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004204463

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006500866

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11178230

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2004204463

Country of ref document: AU

Date of ref document: 20040109

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004204463

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004701172

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004701172

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11178230

Country of ref document: US

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载